The CDC ACIP recommends 2 doses of the 2024-2025 COVID-19 vaccine for those age 65+ years and 2 or more doses for immunocompromised individuals.

Netflix earnings after the bell drive focus in tech stocks. Dow and S&P climb as optimism over trade policy fuels market ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future ...

FreshBooks also has a mobile app for iOS and Android. $19 per month or $228 annually. Designed for self-employed professionals. Covers five billable clients. Unlimited and customized invoices.

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

Moderna MRNA announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”) ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

The public health risk remains low, but bird flu variants have proven to be unpredictable, which is why the virus is a top ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Robert F. Kennedy Jr. petitioned the FDA to revoke authorization of the shots when they were in high demand and thousands of ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $33.76 which represents a decrease of $-1.01 or -2.90% from the prior close of $34.77. The stock opened at $34.75 and touched a low of $33.34 ...